| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On May 28, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| 2001D-0357
|
| Studies to Evaluate the Safety of Residues of Veterinary
|
|
|
|
|
| 2003P-0551
|
| Citalopram Hydrobromide Capsules
|
|
|
|
|
| 2004D-0156
|
| International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); Guidance for Industry on b
|
|
|
|
|
| 2004D-0193
|
| Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
|
|
| 2004P-0139
|
| approval of generic versions of Concerta (methylphenidate HCI extended-release tablets are both bioequivalent and clinically equivalent to the innovator product
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET
14031
|
| Santical USA
|
| Vol #:
|
| 120
|
|
|
|
|
| LET
14032
|
| Santical USA
|
| Vol #:
|
| 120
|
|
|
|
|
| LET
14033
|
| Market America, Inc.
|
| Vol #:
|
| 120
|
|
|
|
|
| LET
14034
|
| Metagenics, Inc.
|
| Vol #:
|
| 120
|
|
|
|
|
| LET
14035
|
| Daxen, Inc.
|
| Vol #:
|
| 120
|
|
|
|
|
| 2000N-1571
|
| Enrofloxacin for Poultry: Opportunity for Hearing
|
|
|
|
|
| EMC 777
|
| Matthew Brown
|
| Vol #:
|
| 271
|
|
|
|
|
| EMC 778
|
| Ted Allen
|
| Vol #:
|
| 271
|
|
|
|
|
| EMC 779
|
| Eldon Johnson
|
| Vol #:
|
| 271
|
|
|
|
|
| 2001D-0357
|
| Studies to Evaluate the Safety of Residues of Veterinary
|
|
|
|
|
| GDL
2
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2003P-0551
|
| Citalopram Hydrobromide Capsules
|
|
|
|
|
| AMD
1
|
| Frommer Lawrence & Haugh LLP
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004D-0156
|
| International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); Guidance for Industry on b
|
|
|
|
|
| C
1
|
| Animal Health Institute
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004D-0193
|
| Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
|
|
| BKG 1
|
| Background Material
|
| Vol #:
|
| 2
|
|
|
|
|
| GDL
1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0139
|
| approval of generic versions of Concerta (methylphenidate HCI extended-release tablets are both bioequivalent and clinically equivalent to the innovator product
|
|
|
|
|
| C
2
Tabs
1-19, 20
|
| Heller Ehrman Attorneys
|
| Vol #:
|
| 4
|
|
